---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-26-000093"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2026-07-14T20:29:25+00:00"
generated_at: "2026-07-14T20:30:05.883348+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# West Pharmaceutical renews crosslicense and distribution agreements with Daikyo for 10 years

## Summary
- West holds 49% ownership in Daikyo; new agreements effective July 14, 2026, replace 2017 agreements as amended.
- Crosslicense covers joint development of closures, vials, cartridges, syringes, and medical device components.
- West gets exclusive license from Daikyo outside Japan (with exceptions); Daikyo gets non-exclusive license from West.
- West is exclusive distributor of Daikyo products outside Japan; Daikyo is non-exclusive distributor of West products in Japan.
- Agreements are royalty-free except for a fixed royalty on certain patents; each has a 10-year term with change-of-control termination.

## SEC filing metadata
- accession: 0000105770-26-000093
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2026-07-14T20:29:25+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577026000093/0000105770-26-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577026000093/wst-20260714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-26-000093
- JSON: https://secwatch.observer/filing/0000105770-26-000093.json
- Plain text: https://secwatch.observer/filing/0000105770-26-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.